Tempus AI Surges 30% in a Week on Cancer Test Launch, but Trades at -618x Earnings
NEW YORK, April 19 —
Tempus AI gained 30% in a single week after launching a new cancer test kit and signing a genomics partnership. Shares closed at $55.87.
- TEM shares jumped 13.9% in one session on the cancer test kit announcement, contributing to a 30% weekly gain
- The stock trades at -618x forward P/E on $1.3bn trailing twelve-month revenue — Wall Street expects losses to continue
- Next quarterly earnings will show whether diagnostics revenue is accelerating and whether the new test kit hits any FDA milestones
What Actually Happened
Two catalysts hit back-to-back. Tempus partnered with Predicta Biosciences to widen access to the GenoPredicta ultrasensitive whole-genome sequencing assay. Then the company announced a new cancer test kit, sparking the 13.9% single-day jump. Cathie Wood's ARK Innovation ETF bought $2.5mn worth of shares, adding fuel. ARK buying a money-losing AI diagnostics company is not contrarian — it's pattern. But the purchase signals institutional interest to retail traders, and retail tracks ARK flows closely.
The Catch
A -618x forward P/E means one thing: this company is nowhere near profitability. Analysts expect Tempus to keep burning cash even as revenue grows. The $1.3bn in trailing revenue looks large until you see that the stock is priced as if profits are years away.
Partnerships and product launches generate headlines. They do not generate earnings. The oncology diagnostics market is also crowded — Guardant Health, Exact Sciences, and Natera all compete for testing dollars, and each is further along in commercialization. A 30% weekly run on a partnership and a test kit launch, not an FDA approval or an earnings beat, bakes in news that hasn't turned into results yet.
Bottom Line
The GenoPredicta partnership and cancer test kit do expand Tempus's precision oncology product line. That's real. But a 30% move in five trading days on pre-revenue catalysts is the market paying tomorrow's prices today.
For growth investors, the next earnings report is the test: does diagnostics revenue accelerate enough to justify this valuation, or was this a momentum trade dressed up as a fundamental story? The number that matters is diagnostic segment revenue growth, quarter over quarter.
For a full breakdown of Tempus AI's financials and valuation, generate a free Basis Report here.
Basis Report does not hold positions in securities discussed. This is not investment advice.